Prevention of the "no reflow" phenomenon in the canine heart by mioflazine.

Abstract

The effects of oral pretreatment with mioflazine (2.5 mg X kg-1) on regional myocardial reflow, infarct size reduction and hemodynamic recovery were studied in 24 anesthetized open-chest dogs undergoing 90 minutes of acute left anterior descending coronary artery (LAD) occlusion followed by 150 minutes of reperfusion. Regional myocardial blood flow was measured with tracer microspheres, and infarct size was determined by triphenyl tetrazolium chloride staining. Pretreatment with mioflazine resulted in a reduced diastolic aortic pressure (p less than 0.05) and an elevated cardiac output and LV dpdt max (p less than 0.05). These effects persisted throughout the experiment. In control animals (n = 12) a hyperemic reflow response was found in the perfusion area of the LAD during the first minutes of reperfusion. After 150 min of reperfusion, however, the viable myocardium of the LAD area became underperfused, and almost no reflow was found in the infarcted zones. In the animals pretreated with mioflazine (n = 12) the hyperemic response persisted throughout the reperfusion phase and the no-reflow phenomenon was prevented. Infarct size (expressed as percentage of perfusion area) tended to be smaller in this group: 23.7 +/- 12.4% versus 33.7 +/- 19.2% (p greater than 0.05). Left atrial pressure increased during LAD occlusion in both groups but normalized completely in the drug-pretreated animals (p less than 0.05). It is concluded that pretreatment with mioflazine prevents the no-reflow phenomenon after reperfusion of an evolving infarction, tends to reduce infarct size and improves hemodynamic recovery.

• Authors: W Flameng, R Xhonneux, J Vanhaecke, A Van de Water, M Suy
• Journal: Basic research in cardiology (Basic Res Cardiol) 1985 Jan-Feb Vol. 80 Issue 1 Pg. 27-36 ISSN: 0300-8428 [Print] Germany
• PMID: 3985924 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Cardiovascular Agents
• Piperazines
• mioflazine

Topics

• Animals
• Cardiovascular Agents (pharmacology)
• Coronary Circulation (drug effects)
• Dogs
• Female
• Hemodynamics (drug effects)
• Male
• Myocardial Infarction (drug therapy, pathology)
• Myocardium (pathology)
• Piperazines (pharmacology)
• Premedication